In-vitro, In-vivo and Molecular Docking Studies on Dietary SupplementContaining Polar and Non-Polar fractions of Persea Americana forManagement of Diet-related Chronic Diseases
AFPDS can be considered a new agent for the prevention and treatment of dietrelated chronic diseases, such as diabetes and cancer, due to its anti-inflammatory, antioxidant, anticancer, and anti-diabetic activities, as demonstrated through in-vivo, in-vitro, and molecular docking studies.
Authors
- Ibrahim M. Hamed (ORCID: https://orcid.org/0000-0002-1995-4811)
- Hoda B. Mabrok (ORCID: https://orcid.org/0000-0002-3839-0062)
- Doha A. Mohamed (ORCID: https://orcid.org/0000-0003-0606-9378)
- Gamil E. Ibrahim (ORCID: https://orcid.org/0000-0001-5826-7961)
Institutions
- National Research Centre (EG)
Publication Details
- Journal
- Current Pharmaceutical Biotechnology
- Published
- 2025-03-05
- DOI
- https://doi.org/10.2174/0113892010357755250227060845
- Primary Topic
- Natural Antidiabetic Agents Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00